
Overview
Synthaverse is a Polish biotechnology company that has been operating since 1944, specializing in the development of immunotherapy solutions for various medical fields, including oncology, urology, gynecology, and tuberculosis treatment. The company offers products such as ONKO BCG, DAVOSTER, and DISTREPTAZA, aimed at supporting patients and the medical community.
Financials
Revenue history (in m)
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 245 days for 2023). All were audited by a statutory auditor.
- 202506/07/2026
- 202404/08/2025
- 202317/03/2025
- 202203/07/2023
- 202128/07/2022
- 202012/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 2.85
- High
- PLN 2.87
- Low
- PLN 2.71
- Volume
- 94.59K
- Avg. vol.
- 68.92K
- Market cap
- PLN 210.95M
- P/E ratio
- –
- EPS
- -PLN 0.28
- Shares outstanding
- 76.02M
- 52-week
- PLN 2.45 – 2.89
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLBMDLB00018
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 3.47m | USD -182.87k | USD -745.54k |
| Q1 2026 | USD 3.68m | USD -179.90k | USD -974.07k |
| Q4 2025 | USD 4.40m | USD -1.96m | USD -1.73m |
| Q3 2025 | USD 1.20m | USD -1.86m | USD -1.94m |
Results for Q3 2026:Nov 30, 2026
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
Industry
Offer
- Oncological immunotherapy
- Urological preparations
- Gynecological preparations
- BCG tuberculosis vaccine
- Laboratory reagents
- Contract manufacturing
Websites
- synthaverse.comSynthaverse S.A.
Public procurement
3 tenders recorded as contractor, with a total value of $11,169.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Dec 30, 2022 | Supply of chemical and diagnostic reagents and standards for Wojewódzka Stacja Sanitarno-Epidemiologiczna w Bydgoszczy | $1,465$1,465 | Wojewódzka Stacja Sanitarno - Epidemiologiczna w Bydgoszczy | |
| Aug 25, 2022 | Successive supply of chemical reagents and microbiological materials for Wojewódzka Stacja Sanitarno-Epidemiologiczna w Rzeszowie – procedure II | $8,410$8,410 | Wojewódzka Stacja Sanitarno - Epidemiologiczna w Rzeszowie | |
| Mar 29, 2022 | Supply of laboratory and chemical reagents together with the lease of analysers and instruments – Lot No. 12: Supply of bacteriological media – Lowenstein-Jensen medium, drug resistance test kits | $1,294$1,294 | Samodzielny Zespół Publicznych Zakładów Lecznictwa Otwartego Warszawa Praga-Północ |
Synthaverse has been a party to 13 cases before the National Appeal Chamber (since 2026). It filed 13 appeals (1 upheld, 1 dismissed, 11 discontinued).
| Date | Subject of dispute | Outcome | Other party | |
|---|---|---|---|---|
| Oct 7, 2026 | I don't know | Discontinued | Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Wielospecjalistyczny w Jaworznie | |
| Sep 17, 2026 | I don't know | Discontinued | Szpital Specjalistyczny im. Jędrzeja Śniadeckiego w Nowym Sączu | |
| Sep 11, 2026 | Procurement | Discontinued | Wojewódzki Szpital Specjalistyczny im. Błogosławionego księdza Jerzego Popiełuszki we Włocławku |
Trademarks
The company holds 20 active trademarks registered with the Polish Patent Office. 5 marks have expired or were not registered. The first mark was filed in 1993.
| Mark | Protected until | |
|---|---|---|
| CINVIKLUD (word) | Nov 13, 2034 | |
| AMSUNEFIL (word) | Nov 13, 2034 | |
| SINRUDOLIF (word) | Nov 13, 2034 | |
| AVISTUAR (word) | Nov 13, 2034 | |
| FILCAZMIR (word) | Nov 13, 2034 |
Job offers
The company has its own careers page: synthaverse.com/pl/kariera.
Authorized Representatives
Manner of representation
For making declarations of will concerning the rights and obligations of the company and for signing on behalf of the company, the following are authorized: in the case of a one-person management board, the President independently, or two commercial proxies jointly. In the case of a multi-member management board: the President of the Management Board jointly with a member of the management board, or two members of the management board jointly, or a member of the management board jointly with a commercial proxy, or two commercial proxies jointly. Matters exceeding the ordinary management of the company require a resolution of the management board.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2003-09-30.
15 1050 1953 1000 0090 3218 4583
23 1050 1953 1000 0090 3216 8628
46 1050 1953 1000 0090 8135 4392
Debt
1 closed proceeding recorded in KRZ history.
| Registration date | Proceeding type | Status | |
|---|---|---|---|
| Oct 25, 2024 | Declaration of arrangement performance in restructuring | Closed |
MSiG notices
36 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Oct 18, 2024 | Bankruptcy notice | |
| Jul 24, 2024 | Bankruptcy notice | |
| Apr 18, 2024 | Bankruptcy notice | |
| Jan 17, 2024 | Bankruptcy notice | |
| Oct 30, 2023 | Bankruptcy notice |
Public aid
43 public aid cases recorded, with a total value of $24,963,309.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 27, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $5,048$5,048 | Lubelski Park Naukowo -Technologiczny S.A. | |
| Mar 16, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $3,952$3,952 | Prezydent Miasta Lublin | |
| Dec 19, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $2,009$2,009 | Prezes Banku Gospodarstwa Krajowego |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $18,006,964.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2022-06-01 | Implementation of R&D results in the innovative technology for manufacturing a product for bladder cancer immunotherapy based on the Moreau substrain of attenuated BCG mycobacteria | $9.7M$9,681,039 | Operational Programme Smart Growth | |
| 2021-01-01 | Promotion of Onko BCG, a medicine used to treat superficial, epithelial, non-invasive bladder tumours, in foreign markets | $76,566$76,566 | Operational Programme Smart Growth | |
| 2020-12-01 | BCG Biotechnology Innovation Centre | $7.5M$7,481,911 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| Integrated permit | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Biogen Poland sp. z o.o. | $42,610,046.12 | biogen-poland.pl | ||
| Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss Biomed S.A. | $40,633,950.51 | biomed.pl | ||
| Biovico sp. z o.o. | $32,716,605.20 | biovico.com | ||
| Bio-Gen sp. z o.o. | $17,565,830.56 | bio-gen.pl | ||
| Reig Jofre sp. z o.o. | $16,662,733.82 | reigjofre.pl | ||
| Paso-Trading sp. z o.o. | $12,314,433.40 | paso-trading.pl | ||
| Biofaktor sp. z o.o. | $10,761,755.73 | biofaktor.pl | ||
| HAL Allergy sp. z o.o. | $9,112,910.50 | hal-allergy.com | ||
| Fortis Pharmaceuticals sp. z o.o. | $6,911,557.57 | fortispharmaceuticals.pl | ||
| Celltrion Poland sp. z o.o. | $1,237,076.36 | celltrion.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-07-29 | Share capital increase (7,577,057.50 PLN → 7,601,940.30 PLN) | |
| 2025-11-19 | Share capital increase (7,077,057.50 PLN → 7,577,057.50 PLN) | |
| 2024-12-12 | Share capital increase (7,052,197.30 PLN → 7,077,057.50 PLN) | |
| 2024-02-14 | Share capital increase (7,026,041.00 PLN → 7,052,197.30 PLN) | |
| 2023-07-10 | Name change ("biomed-Lublin" Wytwórnia Surowic I Szczepionek → "synthaverse") |
FAQ
Last updated: 2026-10-03





